May. 8 at 5:04 PM
$AIM $BMY $MRK $PFE
AIM didn’t raise cash because the trial failed — they raised it because the results were strong enough to keep pushing forward. The 50% response rate with Merck’s Keytruda gave them a real path toward bigger Phase 3 trials and eventually FDA approval.
The
$4.2M raise gives AIM breathing room to finish collecting survival data, advance the pancreatic cancer program, and keep operations moving. The market focused on dilution from the
$0.48 offering, which temporarily capped the stock reaction, but big investors wouldn’t be locking in millions around
$0.48–
$0.60 if they didn’t see upside ahead.
